AP Biosciences’ Dual Platforms for Cancer Immunotherapy

In an interview with Spike Lo at BIO International Convention 2025, Taiwan-based AP Biosciences, Inc. presented its dual technology platforms, OmniMab, a versatile phage-display library for rapid antibody discovery, and T-Cube, a bispecific format designed for tumor-specific T-cell activation.

Early data from preclinical studies suggest the potential for tumor-specific immune activation without major safety concerns. AP’s lead candidates, AP402 and AP505, are now advancing through clinical development, with trials initiated in Australia and discussions underway with global partners.

Checkout the full in-depth interview here:
English – https://bit.ly/4kAYqkB
Chinese – https://reurl.cc/A3knDe